Last update 24 Jun 2025
Draig Therapeutics Ltd

Draig Therapeutics Ltd

Private Company|2024|Australia|
10-50
|
draigtherapeutics.com

Overview

Tags

Nervous System Diseases
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Top 5 Drug TypeCount
Chemical drugs2
Top 5 TargetCount
GABRA2 x GABRA31
GABRA5(Gamma-aminobutyric acid A receptor alpha-5)1

Related

2
Drugs associated with Draig Therapeutics Ltd
DT-301
Target
GABRA2 x GABRA3
Mechanism
GABRA2 positive allosteric modulators [+1]
Active Org.
Draig Therapeutics LtdDraig Therapeutics Ltd
Originator Org.
Draig Therapeutics LtdDraig Therapeutics Ltd
Active Indication
Nervous System Diseases
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
DT-201(Draig Therapeutics)
Target
GABRA5
Mechanism
GABRA5 negative allosteric modulator
Active Org.
Draig Therapeutics LtdDraig Therapeutics Ltd
Originator Org.
Draig Therapeutics LtdDraig Therapeutics Ltd
Active Indication
Nervous System Diseases
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Draig Therapeutics Ltd
Login to view more data
0 Patents (Medical) associated with Draig Therapeutics Ltd
Login to view more data
100 Deals associated with Draig Therapeutics Ltd
Login to view more data
100 Translational Medicine associated with Draig Therapeutics Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
DT-201(Draig Therapeutics)
 ( GABRA5 )		Nervous System Diseases
More
Preclinical
DT-301
 ( GABRA2 x GABRA3 )		Nervous System Diseases
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free